PRINCETON, N.J. & TOKYO–(BUSINESS WIRE)–Data from the AZTOUND trial evaluating oral azacitidine and cedazuridine in patients with MDS or CMML will be shared at the 68th ASH Annual Meeting.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.